• Citer

Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: Further evidence for survival and safety and implications for early treatment

par Vincent, Jean Louis ;Bernard, Gordon;Beale, Richard;Doig, Christopher;Putensen, Christian;Dhainaut, Jean-Francois;Artigas, Antonio;Fumagalli, Roberto;Macias, William;Wright, Theressa;Wong, Kar;Sundin, David;Turlo, Mary Ann;Janes, Jonathan
Référence Critical care medicine, 33, 10, page (2266-2277)
Publication Publié, 2005-10

Article révisé par les pairs

• Détails

Titre:	Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: Further evidence for survival and safety and implications for early treatment
Auteur:	Vincent, Jean Louis; Bernard, Gordon; Beale, Richard; Doig, Christopher; Putensen, Christian; Dhainaut, Jean-Francois; Artigas, Antonio; Fumagalli, Roberto; Macias, William; Wright, Theressa; Wong, Kar; Sundin, David; Turlo, Mary Ann; Janes, Jonathan
Informations sur la publication:	Critical care medicine, 33, 10, page (2266-2277)
Statut de publication:	Publié, 2005-10
Sujet CREF:	Sciences bio-médicales et agricoles
Mots-clés:	Activated protein C
	Clinical trial
	Drotrecogin alfa (activated)
	Early treatment
	ENHANCE
	Severe sepsis
Note générale:	SCOPUS: ar.j
Langue:	Anglais
Identificateurs:	urn:issn:0090-3493
	info:doi/10.1097/01.CCM.0000181729.46010.83
	info:scp/26444604781